Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis

Ferrandiz C, Garcia A, Blasco AJ, Lazaro P

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22126264

DOI
10.1111/j.1468-3083.2011.04357.x

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Adalimumab; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized /economics /therapeutic use; Cost-Benefit Analysis; Dermatologic Agents /economics /therapeutic use; Etanercept; Humans; Immunoglobulin G /economics /therapeutic use; Infliximab; Psoriasis /drug therapy; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor /therapeutic use; Ustekinumab

AccessionNumber
22012023257

Date bibliographic record published
03/01/2013